MX2023005841A - Anticuerpos anti-marco y usos de estos. - Google Patents
Anticuerpos anti-marco y usos de estos.Info
- Publication number
- MX2023005841A MX2023005841A MX2023005841A MX2023005841A MX2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A MX 2023005841 A MX2023005841 A MX 2023005841A
- Authority
- MX
- Mexico
- Prior art keywords
- marco
- antibodies
- marco antibodies
- generating
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115272P | 2020-11-18 | 2020-11-18 | |
| US202163244662P | 2021-09-15 | 2021-09-15 | |
| PCT/US2021/059955 WO2022109178A1 (en) | 2020-11-18 | 2021-11-18 | Anti-marco antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005841A true MX2023005841A (es) | 2023-08-16 |
Family
ID=81588283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005841A MX2023005841A (es) | 2020-11-18 | 2021-11-18 | Anticuerpos anti-marco y usos de estos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11572407B2 (https=) |
| EP (1) | EP4247419A4 (https=) |
| JP (1) | JP2023549555A (https=) |
| KR (1) | KR20230121759A (https=) |
| AU (1) | AU2021382658A1 (https=) |
| CA (1) | CA3198579A1 (https=) |
| IL (1) | IL302874A (https=) |
| MX (1) | MX2023005841A (https=) |
| TW (1) | TW202237648A (https=) |
| WO (1) | WO2022109178A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11572407B2 (en) | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
| CA3238769A1 (en) * | 2021-11-23 | 2023-06-01 | William Brondyk | Anti-ngf antibodies and uses thereof |
| WO2024059256A1 (en) * | 2022-09-15 | 2024-03-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer |
| WO2024081807A2 (en) * | 2022-10-12 | 2024-04-18 | Massachusetts Institute Of Technology | Library-scale methods for polypeptide functional analysis |
| WO2025102054A1 (en) * | 2023-11-09 | 2025-05-15 | Massachusetts Institute Of Technology | Methods of screening for secreted functional molecules |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916766A (en) | 1996-05-23 | 1999-06-29 | Smithkline Beecham Corporation | Human marco scavenger receptor |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| JP2010534335A (ja) * | 2007-07-24 | 2010-11-04 | アイエスエス イミューン システム スティミュレーション アーベー | 全身性エリテマトーデス感受性を予測するための方法及び手段 |
| WO2009114547A2 (en) | 2008-03-10 | 2009-09-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced dendritic cells for cancer immunotherapy |
| KR20130108295A (ko) * | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| EP3302558A4 (en) | 2015-06-01 | 2019-01-16 | The Rockefeller University | ANTI-TUMOR MEDIUM AND METHOD OF USE |
| WO2017062363A1 (en) | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN110709422B (zh) | 2017-04-19 | 2023-12-26 | 马伦戈治疗公司 | 多特异性分子及其用途 |
| TWI828625B (zh) | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| EP3668899A4 (en) | 2017-08-18 | 2020-09-02 | Celdara Medical, LLC | CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES |
| WO2019068007A1 (en) | 2017-09-28 | 2019-04-04 | Immpact-Bio Ltd. | UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) |
| US20210000920A1 (en) | 2017-12-22 | 2021-01-07 | Atossa Therapeutics, Inc. | Intraductal methods of treatment of breast disorders |
| AU2019228381B2 (en) | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| AU2019394364A1 (en) * | 2018-12-05 | 2021-06-17 | The Council Of The Queensland Institute Of Medical Research | Rank antagonists and uses therefor |
| EP3906055A4 (en) | 2019-01-04 | 2023-01-04 | Trio Pharmaceuticals, Inc. | MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES |
| JP2022519378A (ja) | 2019-02-08 | 2022-03-23 | グッド ティー セルズ、 インコーポレイテッド | がん治療のためのｔ細胞の活性化方法 |
| US20220152148A1 (en) | 2019-03-18 | 2022-05-19 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
| JP2022536598A (ja) | 2019-05-07 | 2022-08-18 | イミューニコム， インコーポレイテッド | 体外アフェレーシスによるチェックポイント阻害剤に対する応答の上昇 |
| JP2022536684A (ja) | 2019-06-11 | 2022-08-18 | マイエロイド・セラピューティクス，インコーポレーテッド | マクロファージ特異的エンゲージャー組成物およびその使用方法 |
| EP4003994A4 (en) | 2019-07-31 | 2023-09-13 | Oncour Pharma, Inc. | TREATMENT OF EVASIVE IMMUNE TUMORS |
| US11572407B2 (en) | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
-
2021
- 2021-11-18 US US17/529,927 patent/US11572407B2/en active Active
- 2021-11-18 JP JP2023529918A patent/JP2023549555A/ja active Pending
- 2021-11-18 KR KR1020237020512A patent/KR20230121759A/ko active Pending
- 2021-11-18 IL IL302874A patent/IL302874A/en unknown
- 2021-11-18 MX MX2023005841A patent/MX2023005841A/es unknown
- 2021-11-18 CA CA3198579A patent/CA3198579A1/en active Pending
- 2021-11-18 WO PCT/US2021/059955 patent/WO2022109178A1/en not_active Ceased
- 2021-11-18 AU AU2021382658A patent/AU2021382658A1/en active Pending
- 2021-11-18 TW TW110143070A patent/TW202237648A/zh unknown
- 2021-11-18 EP EP21895613.4A patent/EP4247419A4/en active Pending
-
2022
- 2022-12-19 US US18/068,237 patent/US12378311B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11572407B2 (en) | 2023-02-07 |
| IL302874A (en) | 2023-07-01 |
| US20220153832A1 (en) | 2022-05-19 |
| CA3198579A1 (en) | 2022-05-27 |
| EP4247419A4 (en) | 2024-11-06 |
| KR20230121759A (ko) | 2023-08-21 |
| TW202237648A (zh) | 2022-10-01 |
| US12378311B2 (en) | 2025-08-05 |
| WO2022109178A1 (en) | 2022-05-27 |
| AU2021382658A1 (en) | 2023-07-06 |
| US20240084000A1 (en) | 2024-03-14 |
| JP2023549555A (ja) | 2023-11-27 |
| EP4247419A1 (en) | 2023-09-27 |
| WO2022109178A9 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005841A (es) | Anticuerpos anti-marco y usos de estos. | |
| MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
| ZA202309516B (en) | Anti-ccr8 antibodies | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| ZA202204437B (en) | Anti-pd-l1 antibodies and antibody-drug conjugates | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| ZA202206670B (en) | Anti-ly6g6d antibodies and methods of use | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| PH12021550096A1 (en) | Compositions of fcrn antibodies and methods of use thereof | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| ZA202307404B (en) | Anti-met antibodies and uses thereof | |
| MX2023004280A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| PH12020551292A1 (en) | Moscato wine replicas produced from individual components | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MX2025005092A (es) | Anticuerpo anti-trem2 y usos del mismo | |
| MX2025005088A (es) | Métodos para tratar cánceres | |
| MX2024014079A (es) | Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos | |
| PH12021551195A1 (en) | Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof | |
| CL2023003151A1 (es) | Anticuerpos anti-notch2 y métodos de uso | |
| MX2022015206A (es) | Anticuerpos anti-hbv y metodos de uso. | |
| WO2021164704A3 (en) | Enhanced expression system and methods of use thereof | |
| WO2021022111A3 (en) | β-ARRESTIN-MODULATING COMPOUNDS AND METHODS OF USING SAME |